Authors: HARDER S THURMANN PA UNGETHUM W

Citation: S. Harder et al., SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS AND PHARMACODYNAMICS OFTHE ACE-INHIBITOR IMIDAPRIL IN HYPERTENSIVE PATIENTS, British journal of clinical pharmacology, 45(4), 1998, pp. 377-380

Authors: HOOGKAMER JFW KLEINBLOESEM CH NOKHODIAN A OUWERKERK MJA LANKHAAR G UNGETHUM W KIRCH W

Citation: Jfw. Hoogkamer et al., PHARMACOKINETICS OF IMIDAPRIL AND ITS ACTIVE METABOLITE IMIDAPRILAT FOLLOWING SINGLE-DOSE AND DURING STEADY-STATE IN PATIENTS WITH CHRONIC-RENAL-FAILURE, European Journal of Clinical Pharmacology, 54(1), 1998, pp. 59-61

Authors: HOOGKAMER JFW KLEINBLOESEM CH NOKHODIAN A OUWERKERK MJA LANKHAAR G UNGETHUM W KIRCH W

Citation: Jfw. Hoogkamer et al., PHARMACOKINETICS OF IMIDAPRIL AND ITS ACTIVE METABOLITE IMIDAPRILAT FOLLOWING SINGLE-DOSE AND DURING STEADY-STATE IN PATIENTS WITH IMPAIREDLIVER-FUNCTION, European Journal of Clinical Pharmacology, 51(6), 1997, pp. 489-491

Authors: HARDER S THURMANN PA UNGETHUM W

Citation: S. Harder et al., PK-PD MODELING WITH THE ACE-INHIBITOR IMIDAPRIL IN HYPERTENSIVE PATIENTS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 88-88